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Multiple sclerosis (MS) disease is carried through inﬂammatory and degenerative stages. Based on clinical feaures, it can be
subdivided into three groups: relapsing-remitting MS, secondary progressive MS, and primary progressive MS. Multiple sclerosis
has a multifactorial etiology with an interplay of genetic predisposition, environmental factors, and autoimmune inﬂammatory
mechanism in which play a key role CC-chemokines and its receptors. In this paper, we studied the frequency of CCR5 gene Δ32
allele in a cohort ofSicilianRR-MS patients comparingwith generalSicilianpopulation.Also,we evaluatethe associationbetween
this commonly polymorphism and disability development and age of disease onset in the same cohort. Our results show that
presence of CCR5Δ32 is signiﬁcantly associated with expanded disability status scale score (EDSS) but not with age of disease
onset.
1.Introduction
Multiple sclerosis (MS) is a autoimmune chronic disorder of
the central nervous system (CNS) characterized by multifo-
cal inﬂammatory destruction of myelin, axonal damage, loss
of oligodendrocytes, and repair mechanism [1].
MS is a frightening and potentially disabling disease
for young adults that aﬄicts around 2.5 million people
worldwide with an incidence of about 7 per 100,000 persons
every year, a prevalence of around 120 per 100,000, and a
lifetime risk of 1 in 400 [2].
Studiesof MS-twin pairs haverevealedthatthe estimated
concordanceforMSwas3%–5%fordizygoticand25%–30%
for monozygotic twins [3, 4].
O nt h eb a s i so ft h et e m p o r a lc o u r s eo fd i s e a s e ,M Sc a nb e
subdividedintothreeclinicalgroups:relapsing-remitting MS
(RR-MS, characterized by relapses when there is a ﬂare up of
symptoms, followed by remissions when there are not symp-
toms),secondary progressiveMS (SP-MS,aslowand gradual
form that begins with a relapsing-remitting course), and
primary progressive MS (PP-MS, which is expressed, from
the start, by a gradual progression of disability). The most
common form of disease in approximately 85% of the cases
is RR-MS and, typically, the illness passes through phases
of relapse with full recovery, relapse with persistent deﬁcit,
and secondary progression [1, 2]. Patients with RR-MS
accumulate disability from disease onset more slowly than
those with primary progressive multiple sclerosis. Most
therapeutic agents used in MS (e.g., immunosuppressive
and immunomodulatory drugs and cell-cycle interruption
drugs) are only used for RR-MS. These treatments show
some eﬃciency in lessening the relapse rate in RR-MS and
timetoprogressionbutcannotcureMS.Thus,thereisaneed
for new eﬃcient treatments for all types ofMS [5]. The etiol-
ogyofMSisunknownbutlikelymultifactorial,withaninter-
play of genetic predisposition, environmental factors and
autoimmune inﬂammatory mechanism; in fact, this disease
iscarriedthroughtwostages:inﬂammatory anddegenerative
[6, 7]. The migration of inﬂammatory cells is facilitated
by the upregulation of adhesion molecules-1 (ICAM-1),
vascular-cell adhesion molecules-1 (VCAM-1), and platelet
endothelial cell adhesion molecule-1 (PECAM-1) [8]. On2 Multiple Sclerosis International
the other hand, matrix metalloproteinases (MMPs) may
degrade components of the basement membrane, and
chemokines can form concentration gradient, which attract
leukocytesandactivateleukocyteintegrins, increasing adher-
ence and extravasation [9]. Then, the proinﬂammatory
cytokines (e.g., TNF-a, INF-g, IL-2, and IL-12) released
by Th 1 cells and macrophages trigger a chain of events,
resulting in the formation of demyelinated plaque and
damage to axon [8, 10, 11]. Activated T cells enter the CNS
and trigger an inﬂammatory cascade that leads to recruit-
ment of other immune cells. Increasing lines of evidence
have implicated an involvement for chemokines and their
receptors in several neurodegenerative disorders, including
Alzheimer’s disease (AD), Parkinson’s disease (PD), HIV-
associated dementia (HAD), and also in multiple sclerosis
(MS)[12]. Genetic studies indicate that CC-chemokines and
chemokine receptors are involved in the susceptibility to MS
[13], in fact; they play a signiﬁcant role in the migration of
monocytesandTcells.Inparticular,CC-chemokinereceptor
5 (CCR5), a seven-transmembrane spanning G protein-
coupled receptor, is a speciﬁc binding site for the CC-
chemokines like RANTES (CCL5), macrophage inﬂamma-
tory protein MIP 1α (CCL3),and macrophage inﬂammatory
protein MIP 1β (CCL4) [14]. CCR5 encoded by CCR5
gene, located on chromosome 3p21 [15], has been identiﬁed
as a coreceptor for the human immunodeﬁciency virus-1
(HIV-1) [16]. A nonfunctional allele, resulting from a 32-
bp deletion in exon 4, CCR5Δ32, leads to a truncated form
of the functional receptor. Individuals homozygous for a
32-bp deletion allele of CCR5, CCR5Δ32, were resistant to
HIV-1 infection despite repeated exposure [14]. Moreover,
in the CNS, CCR5 is expressed on neurons, astrocytes, and
microglia [17], as well as on endothelium and vascular
smooth muscle cells and on T-helper cells [18]. During MS
pathogenesis, the absence of functional CCR5 on the cell
surface could lead to reduced traﬃcking of leucocytes into
the lesion sites, thus downregulating inﬂammation in brain
tissue. To assess the possible association between CCR5Δ32
and the course of MS, various studies were performed,
and while several studies showed an association between
CCR5Δ32 and a favorable clinical course of MS [19–21],
no correlation was found between this polymorphism and
the course of the disease in other studies [22–24]; however,
the results are in contrast and are not yet clear [25]. Based
upon the key role played by chemokines in the migration
of macrophages and T cells in MS, and the importance of
genetic factors associated and the possible viral or nonviral
stimulation involved in the pathogenesis of the disease, in
this work, we investigated the eﬀect of CCR5Δ32 on age of
onset, course, and severity of disease in cohort of Sicilian
patients with RR-MS.
2.Materialsand Methods
2.1. Patient Samples. Peripheral blood specimens were ob-
tained from 180 RR-MS patients (131 female and 49 male)
recruited fromthe Department ofNeurosciences,Psychiatric
and Anaesthesiological Sciences, University of Messina, Italy.
All patients in this study fulﬁlled the criteria for clini-
cally deﬁned MS [26] and underwent routine diagnostic
CSF and blood tests, and a full neurological examination.
At the time of sample collection, disease type was deﬁned
as relapsing-remitting MS (RR-MS) disease, with Kurtzke
expanded disability status scale scores between 0.0 and 6.5
(EDSS-expandeddisabilitystatusscaleordiseaseprogression
index).
Control group comprised 213 unrelated, healthy donors
without a family history of autoimmune diseases and were
collected during ﬁeld studies conducted in 1999 and 2005.
The samples were taken from several towns in Sicily.
The individual donors were eligible for the present study
if their ancestors were born in the same location and if they
h a dn op r o g e n i t o r si nc o m m o nu pt ot h e i rg r a n d p a r e n t a l
generation.
All parameters (age, age at onset, and EDSS)of male ver-
sus female were matched in the MS patient group as well as
the age of male versus female in the controls. All participants
gave their written informed consent.
2.2. Genotyping. Genomic DNA was isolated using the salt-
ing out method [27].
Eparinized peripheralbloodwascollectedfromcasesand
controlsbeforeanytherapy.PCRwascarriedoutinathermal
cycler (Gene Amp PCR System 9600; PE Applied Bi-
osystems, Foster City, CA) in 50μL volumes containing
a0 . 2 μm concentration of each primer (forward CCR5
primer: 5 -GTCTTCATTACACCTGCAGCTC; reverse: 5 -
GTGAAGATAAGCCTCACAGCC),1U Euro Taq polymerase
(Euroclone Spa Life Sciences Division, Italy) and 0.8μg
genomic DNA as template, under the following conditions:
denaturation at 95◦C for 1.5min, annealing at 56.5◦Cf o r
1min and extension at 72◦C for 50s for 35 cycles, after
an initial 5min denaturation at 95◦C. Aliquot of the PCR
products were separated using agarose gel electrophoresis,
a n dt h e1 9 8b pi nt h ec a s eo ft h ew i l d - t y p ea l l e l ea n d1 6 6b p
in the case of the Δ32 allele were visualized using ultraviolet
light, following ethidium bromide staining.
2.3. Statistical Analysis. For each group (control and pa-
tients), the CCR5Δ32 allele frequencies were calculated by
direct gene counting. Statistical analyses were performed
using “Statistica”package[28].Dataare presentedas mean ±
SD for parametric variables and as percentages for non-
parametric values. Continuous variables were compared
using Student’s t-test to test possible inﬂuence of CCR5Δ32
allele on EDSS score and age onset. With the aim of reducing
possible sources of variance, we included in our analyses
gender, age, and age at disease onset as covariates using
ANOVA method for statistical analysis. All P values were 2-
tailed, and statistical signiﬁcance was set at P<. 05.
3.Results
The demographic data are reported in Table 1 which indi-
cates no signiﬁcant diﬀerences (P<. 05) between overall
MS age versus overall healthy control age. The frequenciesMultiple Sclerosis International 3
Table 1: Demographic and disease-related data of our samples.
Gender n Age Age of onset EDSS at time of examination
Mean ± SD Mean ± SD Mean ± SD
MS patients Male 49 (27%) 45.4 ± 7.7 29.1 ± 7.6 2.3 ± 1.7
Female 131 (73%) 44.6 ± 8.2 29.5 ± 7.9 2.7 ± 1.1
Overall 180 44.8 ± 8.0 29.4 ± 7.8 2.6 ± 1.3
GENDER n AGE
Mean ± SD
Healthy controls
Male 61 (29%) 45 ± 12
Female 152 (71%) 43 ± 11
Overall 213 44 ± 11.4
MS: multiplesclerosis;EDSS: expanded disabilitystatusscale; SD: standard deviation. P<. 05 indicates statisticalsigniﬁcance.
of CCR5Δ32 alleles in patients with MS (fr= 0.06) did not
diﬀer signiﬁcantly from those of controls (fr = 0.06) and
were not inﬂuenced by gender (χ2 = 2.00, P = .13). We
observed a signiﬁcant association between CCR5Δ32 allele
and EDSS scores (t = 2.04, P<. 05). As a consequence,
for reducing possible sources of variance, we introduced
all such variables as covariates in our model. Data showed
that introducing sex, age, and age of onset as covariates,
results remain statistically signiﬁcant. We did not observed
any signiﬁcant association between CCR5Δ32 allele and age
onset (P>. 05) (Table 2).
4.Discussion
Chemokine receptors and their ligands play a key role in
several neurodegenerative diseases, such as MS, when they
are activated inappropriately [34]. The chemokine receptors
expressed by T helper cells may be important reports
allowing the association between multiple sclerosis and CNS
inﬁltrated CD4cellsand monocytes. Forthisreason, itseems
that these receptors may be related to the development of
new lesions in multiple sclerosis [35].
In addition in a T-cell-mediated inﬂammatory disease
like MS, the expression of chemokines and their receptors
is markedly regulated by proinﬂammatory cytokines, for
example, tumour necrosis factors or interleukins [36]. All
these evidences are also conﬁrmed by various studies that
showing an elevated expression of CC-chemokine in the
CNS in MS patients: researchers have focused on chemokine
receptor, their ligands, and they have highlighted the role
they have played in the development and clinical course of
MS [37–39]. In particular, the role of CCR5 in MS is further
strengthened by recent ﬁnding of elevated CCR5 levels in
CD8(+) cells in MS patients [36].
From our study, it was found that the CCR5Δ32 allele
frequency in Sicilian RR-MS patients (fr = 0.06) is
comparable to that found in the general population (fr =
0.06) [40]. Our results, on the one hand, are consistent with
those of some studies [20] and, on the other hand, are not
conﬁrmed by other studies [29, 31].
In fact, Otaegui et al. reported a lower frequency of the
CCR5Δ32 allele in MS patients compared with the control
population in Basque, Spain [31]. Indeed, in the Iranian
population, Shahbazi et al. demonstrated that the Δ32 allele
frequency was higher among MS patients than in control
[29]. These conﬂicting data may result from several factors
as sample size, environmental factors, and diﬀerences in
ethnicity [41].
With regard to the association Δ32CCR5 allele and
clinicalcourse of MS thedata in the literatureare conﬂicting.
In fact, various studies described an association of the
Δ32CCR5 allele with a favorable clinical course of MS
[19–21], while others have failed to show any signiﬁcant
correlation between this polymorphism and the course of
the disease [22, 23] (an overview of main association studies
is summarized in Table 3). Our data showed an association
of the CCR5Δ32 allele with expanded disability status scale
score (t = 2.04, P<. 05) in RR-MS patients, suggesting
that its presence contributes to a slower rate of disease pro-
gression. From these results appears a lower expression of
a functional CCR5 receptor that might inﬂuence the rate
of disability development, and then harboring the mutated
CCR5 allele can be considered a favorable prognostic factor
in MS.
However, as opposed to another recent report [19], we
did not ﬁnd a diﬀerence in the age at disease onset between
the Δ32CCR5 carriers and noncarriers (P>. 05). In our
opinion, it is important to note that the data shown in this
work are not inﬂuenced by factors such as age, age of onset
disease, and gender (see at the results in Table 2).
Overall, the genetic susceptibility to MS remains an open
question. Much of the future research interest will focus to
better understand the genetic heterogeneity of this disease
and the therapeutic needs individual though the replication
of candidate gene association analysis is diﬃcult in MS as is
often happens with complex genetic diseases. The broad sys-
tem of chemokines and their receptors may be an important
keyin the search foranswers tothese questions. More studies
are needed to reveal the exact role of chemokine network
and its association with other factors in the pathogenesis
of this disease. Our data suggest that the presence of this
CCR5 polymorphism in patients with RR-MS might help
in designing a therapeutic regimen and might serve as a
prognostic marker and then that CCR5 antagonists could be
considered potential targets for therapeutic intervention in
MS.4 Multiple Sclerosis International
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Table 3: Overview of major association studies.
Patients country Clinical variable Statistical method Results References
Iran MS development ANOVA Yes (predisposing factor) [29]
Brazil Age of onset; EDSS ANOVA; chi-square test;
Mann-Whitney U-test
Potential favorable
prognostic biomarker [25]
Denmark EDSS Mann-Whitney U-test No associations [30]
Spain Etiopathogeny of the
disease Not available Yes (protective role) [31]
Croatia; Slovenia Age of disease onset or
progression of the disease Not available No associations [23]
USA Age of onset; EDSS Student’s t-test; ANOVA No associations [22]
Northern Ireland
Age of onset;
susceptibility to develop
MS
Not available No associations [24]
Finland Susceptibility to develop
MS chi-square test; ANOVA No associations [32]
Israel EDSS Not available Potential favorable
prognostic biomarker [20]
Germany Susceptibility to develop
MS ANOVA No associations [33]
USA Age of onset Not available
Age of onset was
approximately 3 years later
in patients carrying the
CCR5Δ32 deletion
[19]
Denmark Susceptibility to develop
MS ANOVA; Student’s t-test Lower risk [21]
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